Raghuwanshi Abhijit D, Jambhore Minty W, Viswanath Vishalakshi, Gopalani Vinay
Department of Dermatology, Disha Skin and Laser Institute, Thane, Maharashtra, India.
Indian J Dermatol Venereol Leprol. 2018 Jan-Feb;84(1):49-53. doi: 10.4103/0378-6323.187684.
Targeted phototherapy is a recent advance in the treatment of vitiligo, involving selective treatment of vitiligo patches with no effect on surrounding areas. Although it has been in use for a few years, little data is available regarding its safety and efficacy.
A retrospective study to determine efficacy and safety of targeted phototherapy in vitiligo.
One hundred and thirty four patients (male: 53, female: 81) who received targeted phototherapy and completed 11 or more sittings were included. Treatment was given once a week using the Lumera phototherapy system, a broadband ultraviolet B source, starting at 150 mJ/spot and after excluding a sunburn reaction, with increments of 50 mJ every week up to a maximum of 1000 mJ/patch. Chi-square test for linear trends was used for statistical analysis.
The most common sites involved were the legs and a majority (70.9%) had non-segmental vitiligo. Response was mild in 78 (58.2%) patients, moderate in 50 (37.3%) and excellent in 6 (4.5%) patients. Response was directly proportional to the number of sittings with more patients showing moderate and excellent responses with an increase in the number of sittings. The most common site for an excellent response was the trunk while the lower limbs were involved in most cases with a moderate or mild response. Side effects were seen in 27 (20.2%) patients, the commonest being erythema.
This is a retrospective uncontrolled study. Further, the effects of adjuvant treatment were not assessed.
Targeted phototherapy is a useful treatment for vitiligo with mild adverse effects, though response is mild or moderate and appears to be directly proportional to the number of treatments received.
靶向光疗是白癜风治疗领域的一项最新进展，它能够选择性地治疗白癜风斑块，而不会对周围区域产生影响。尽管其已应用数年，但关于其安全性和疗效的数据却很少。
进行一项回顾性研究，以确定靶向光疗治疗白癜风的疗效和安全性。
纳入134例接受靶向光疗且完成11次或更多次治疗的患者（男性53例，女性81例）。使用Lumera光疗系统（一种宽带紫外线B光源）每周进行一次治疗，起始剂量为150 mJ/光斑，排除晒伤反应后，每周增加50 mJ，直至最大剂量1000 mJ/斑块。采用线性趋势卡方检验进行统计分析。
最常受累的部位是腿部，大多数患者（70.9%）患有非节段性白癜风。78例（58.2%）患者反应轻微，50例（37.3%）患者反应中等，6例（4.5%）患者反应良好。反应与治疗次数成正比，随着治疗次数增加，更多患者表现出中等和良好反应。反应良好最常见的部位是躯干，而大多数出现中等或轻微反应的病例累及下肢。27例（20.2%）患者出现副作用，最常见的是红斑。
这是一项回顾性非对照研究。此外，未评估辅助治疗的效果。
靶向光疗是一种治疗白癜风的有效方法，不良反应轻微，尽管反应为轻度或中度，且似乎与接受的治疗次数成正比。
